Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D40NQW
|
|||
| Drug Name |
GRN-300
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [1] | |
| Company |
Green3Bio
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Salt-inducible kinase 2 (SIK2) | Target Info | Inhibitor | [2] |
| SIK family kinase 3 (SIK3) | Target Info | Inhibitor | [2] | |
| Pathway Interaction Database | LKB1 signaling events | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04711161) Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Green3Bio | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.